LSC
TRIB

Lyon Street Capital’s Trinity Biotech TRIB Stock Holding History

Lyon Street Capital’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-940
Closed -$1.61M – 41
2015
Q3 		$1.61M Sell
940
-216
-19% -$521K 1.17% 27
2015
Q2 		$3.13M Sell
1,156
-2,647
-70% -$6.87M 2.25% 16
2015
Q1 		$11M Sell
3,803
-2,012
-35% -$5.58M 4.73% 2
2014
Q4 		$15.3M Buy
5,815
+884
+18% +$2.29M 6.34% 2
2014
Q3 		$13.5M Buy
4,931
+669
+16% +$2.17M 6.33% 2
2014
Q2 		$14.7M Buy
4,262
+528
+14% +$1.88M 6.49% 3
2014
Q1 		$13.6M Buy
3,734
+740
+25% +$2.91M 6.28% 3
2013
Q4 		$11.3M Buy
2,994
+277
+10% +$997K 5.08% 7
2013
Q3 		$8.87M Buy
2,717
+258
+10% +$755K 4.37% 7
2013
Q2 		$6.22M Buy
+2,459
New +$6.12M 3.08% 9

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $856M AUM 70.44% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Lyon Street Capital's TRIB Position: Q4 2015 in Review

Lyon Street Capital sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 940 shares — an estimated $1.61M sold.

Lyon Street Capital first reported a position in TRIB in Q2 2013 and held it in 10 quarters. The position peaked at $15.3M in Q4 2014. 81 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

  • Lyon Street Capital reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
  • Lyon Street Capital sold 940 Trinity Biotech shares in Q4 2015, an estimated $1.61M.
  • Lyon Street Capital first reported a position in Trinity Biotech in Q2 2013 and held it in 10 quarters.
  • Lyon Street Capital's Trinity Biotech position peaked at $15.3M in Q4 2014.
  • 81 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Lyon Street Capital's 13F filing for Q4 2015, filed 16 Feb 2016.